Show simple item record

dc.contributor.authorGiampaolo, S
dc.contributor.authorWójcik, G
dc.contributor.authorSerfling, E
dc.contributor.authorPatra, AK
dc.date.accessioned2018-05-14T13:08:36Z
dc.date.issued2017-03-18
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10026.1/11501
dc.description.abstract

The role of IL-2 in HSC maintenance is unknown. Here we show that Il2-/- mice develop severe anomalies in HSC maintenance leading to defective hematopoiesis. Whereas, lack of IL-2 signaling was detrimental for lympho- and erythropoiesis, myelopoiesis was enhanced in Il2-/- mice. Investigation of the underlying mechanisms of dysregulated hematopoiesis in Il2-/- mice shows that the IL-2-Treg cell axis is indispensable for HSC maintenance and normal hematopoiesis. Lack of Treg activity resulted in increased IFN-γ production by activated T cells and an expansion of the HSCs in the bone marrow (BM). Though, restoring Treg population successfully rescued HSC maintenance in Il2-/- mice, preventing IFN-γ activity could do the same even in the absence of Treg cells. Our study suggests that equilibrium in IL-2 and IFN-γ activity is critical for steady state hematopoiesis, and in clinical conditions of BM failure, IL-2 or anti-IFN-γ treatment might help to restore hematopoiesis.

dc.format.extent29625-29642
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherImpact Journals, LLC
dc.subjecthematopoietic stem cells
dc.subjectIL-2
dc.subjectTreg cells
dc.subjectIL-10
dc.subjectIFN-gamma
dc.subjectImmunology and Microbiology Section
dc.subjectImmune response
dc.subjectImmunity
dc.titleInterleukin-2-regulatory T cell axis critically regulates maintenance of hematopoietic stem cells
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/28415569
plymouth.issue18
plymouth.volume8
plymouth.publisher-urlhttp://dx.doi.org/10.18632/oncotarget.16377
plymouth.publication-statusPublished online
plymouth.journalOncotarget
dc.identifier.doi10.18632/oncotarget.16377
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2017-03-06
dc.identifier.eissn1949-2553
dc.rights.embargoperiodNo embargo
rioxxterms.versionofrecord10.18632/oncotarget.16377
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-03-18
rioxxterms.typeJournal Article/Review
plymouth.oa-locationhttp://10.0.72.200/oncotarget.16377


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV